MC
CRL icon

Moors & Cabot’s Charles River Laboratories CRL Stock Holding History

Moors & Cabot’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4
Closed -$3K – 921
2021
Q4 		$3K Buy
+4
New +$1.55K ﹤0.01% 881

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Moors & Cabot's CRL Position: Q2 2026 in Review

Moors & Cabot increased its Charles River Laboratories (CRL) stake by 2% in Q2 2026, buying an estimated $6.05K and bringing the position to 1,731 shares worth $393K. The position accounts for 0.02% of the portfolio, ranked #645.

Moors & Cabot first reported a position in CRL in Q3 2021 and has held it in 20 quarters since. The position peaked at $743K in Q3 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Moors & Cabot held 1,731 shares of Charles River Laboratories worth $393K as of Q2 2026.
  • Moors & Cabot bought 34 Charles River Laboratories shares in Q2 2026, an estimated $6.05K.
  • Charles River Laboratories made up 0.02% of Moors & Cabot's portfolio in Q2 2026, its #645 holding.
  • Moors & Cabot first reported a position in Charles River Laboratories in Q3 2021 and has held it in 20 quarters since.
  • Moors & Cabot's Charles River Laboratories position peaked at $743K in Q3 2021.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.